Cemdisiran, an under-the-skin injection therapy given every three months, significantly reduced disease activity in people with generalized myasthenia gravis (gMG) after six months of treatment. That’s according to data from the Regeneron Pharmaceuticals-sponsored Phase 3 NIMBLE study (NCT05070858), which evaluated cemdisiran as a monotherapy, as well as…
People with generalized myasthenia gravis (gMG) can carry certain types of self-reactive antibodies — proteins that mistakenly target the body’s own cells and tissues — that drive the disease but are treatment resistant, according to a new study by Yale School of Medicine researchers. These self-reactive antibodies, or autoantibodies,…
Using tears to test for self-reactive antibodies to help diagnose ocular myasthenia gravis (OMG) is more accurate than using blood samples, according to a study that found nearly all patients who tested negative for these antibodies in the blood had a positive result in tears. “Tear-based testing offers a…
Enrollment is open in an investigator-initiated clinical trial to evaluate cell therapy NKX019 in people with myasthenia gravis (MG). Nkarta, the therapy’s developer, made the announcement in a company press release. Researchers at the University of California, Irvine, and the University of Kansas Medical Center are leading the…
Vyvgart (efgartigimod alfa-fcab) is faster and more effective at reducing symptoms to a minimum than standard treatment with corticosteroids and/or immunosuppressants in adults with myasthenia gravis (MG), a real-world study showed. Data showed that Vyvgart was particularly effective at easing symptoms affecting muscles involved in breathing, speech, and…
UCB’s injection therapy Rystiggo (rozanolixizumab-noli) has been granted regulatory approval in Canada for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) proteins. Anti-AChR or anti-MuSK antibodies — self-reactive antibodies that target the body’s own healthy…
High levels of lactic acid in the bloodstream immediately after surgery to remove the thymus gland were associated with an increased risk of postoperative myasthenic crisis, or POMC, among people with myasthenia gravis (MG), a study reveals. “These findings offer valuable insights for clinical decision-making and monitoring of prognosis…
Nearly all adults who underwent a stem cell transplant for treatment-resistant myasthenia gravis (MG) achieved remission or had minimal symptoms that did not require further treatment, according to a small study. “Studies investigating the efficacy and safety of [stem cell transplant] in the treatment of refractory [or treatment-resistant] MG…
Short-term use of cyclophosphamide — given in six monthly cycles, followed by maintenance immunotherapy — markedly reduced the clinical severity of hard-to-treat myasthenia gravis (MG), according to a study by researchers in Australia and the U.K. The therapeutic response seen among patients also allowed a reduction in the…
A bacterial enzyme called CU43 potently mitigates the impact of the self-reactive antibodies that drive myasthenia gravis (MG) and other autoimmune diseases, according to data from a preclinical study. The research team, led by scientists at Emory University in Georgia, in collaboration with researchers at Rockefeller University in New…
Get regular updates to your inbox.
